New Jersey is currently home to 1696 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
NCT06173505
Recruiting
The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: New Jersey Center for Cancer Research, Brick, New Jersey
Conditions: Nonsquamous Non-small Cell Lung Cancer
Register for Updates
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT06518837
Recruiting
This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment. Secondary objectives include evaluating 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey
Conditions: Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Register for Updates
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT05736367
Recruiting
To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Breast Cancer
Register for Updates
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
NCT05438732
Recruiting
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
11/27/2024
Locations: Atlantic Eye Physicians, Eatontown, New Jersey
Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Register for Updates
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
NCT06462547
Recruiting
The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
11/26/2024
Locations: Clinilabs Drug Development Corporation, Eatontown, New Jersey
Conditions: Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets Type 2
Register for Updates
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
NCT05351294
Recruiting
To determine if the experimental approach of early radiation oncology involvement alongside standard oncologic care will result in higher HRQL at 6 months compared to the control arm receiving standard oncologic care alone, based on the global subscale score of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: RWJBarnabas Health Jersey City Medical Center, Jersey City, New Jersey
Conditions: Radiation Therapy, Metastatic Cancer
Register for Updates
Personalized Cognitive Integrated Motor Training Using Virtual Reality to Improve Gait and Balance
NCT06473987
Recruiting
Problems with walking and balance are common after traumatic brain injury (TBI). Walking and balance problems limit independence and increase risk for injuries due to falls. The purpose of this research study is to test the effectiveness of training that combines moving and thinking tasks, referred to as Personalized cognitive integrated sensorimotor virtual reality (VR)/augmented reality (AR) training on walking and balance ability. The study will also help to understand the changes in thinking... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/25/2024
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Traumatic Brain Injury
Register for Updates
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373
Recruiting
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/25/2024
Locations: Clinical Trial Site, Palisades Park, New Jersey
Conditions: Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Register for Updates
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
NCT06277037
Recruiting
This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study \[EOS\] visit) from their imdusiran clinical trial (the "parent study"). No interventions will be performed in this study other than blood sample collections, review of curren... Read More
Gender:
ALL
Ages:
Between 20 years and 70 years
Trial Updated:
11/25/2024
Locations: Infectious Disease Care, Hillsborough, New Jersey
Conditions: Long Term Follow-up
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Cooperman Barnabas Medical Center, Livingston, New Jersey
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
Support for Cancer Patients Awaiting News
NCT06199570
Recruiting
This is a behavioral trial study to pilot test a stress management intervention for people with cancer who are undergoing routine cancer scans. The study will involve two pilot testing phases. Initial feasibility will be determined in an Open Trial phase, to inform any needed revisions to the intervention and/or protocol prior to a Pilot Randomized Controlled Trial phase. The Open Trial phase is an unblinded, single-site, single-arm open trial (n=10). The Pilot randomized clinical trial (RCT) ph... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Amanda Khoudary, Hackensack, New Jersey
Conditions: Lung Cancer
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Robert Wood Johnson University Hospital, New Brunswick, New Jersey
Conditions: Myocarditis Acute, Cancer
Register for Updates